Loading…
Vyome Holdings, Inc. is projected to rise to $2.74 by 2027, a +22% move from its current price of $2.25. HIND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.17 | $2.25 | $2.33 | +0.07% |
| Jul 13 | $2.14 | $2.25 | $2.37 | +0.15% |
| Jul 14 | $2.12 | $2.26 | $2.40 | +0.22% |
| Jul 15 | $2.10 | $2.26 | $2.42 | +0.30% |
| Jul 16 | $2.09 | $2.26 | $2.44 | +0.37% |
| Jul 17 | $2.07 | $2.26 | $2.46 | +0.45% |
| Jul 18 | $2.06 | $2.26 | $2.48 | +0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.06 | $2.26 | $2.48 | +0.52% |
| Week 2 | $1.99 | $2.27 | $2.59 | +1.05% |
| Week 3 | $1.94 | $2.29 | $2.69 | +1.57% |
| Week 4 | $1.91 | $2.30 | $2.77 | +2.10% |
| Week 5 | $1.87 | $2.31 | $2.85 | +2.64% |
| Week 6 | $1.85 | $2.32 | $2.92 | +3.17% |
| Week 7 | $1.82 | $2.33 | $2.99 | +3.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company focused on immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
The lead product VT-1953 is a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 for the treatment of inflammatory acne.
In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Vyome Holdings, Inc. (HIND) is currently trading at $2.17 per share, with a market capitalization of $15.23M. It ranks 4688 in market size.
The stock operates within the Healthcare sector and has a focused pipeline in immuno-inflammatory and infectious diseases related to the eye and skin, along with antifungal programs.
The overall price outlook shows gradual gains over time. The 2026 average price is $2.17, rising to a 2050 average of $6.46 with a maximum of $13.28. The implied ROI by 2050 is 197.6%. The sequence of forecasted years indicates notable upside from 2027 onward, with progressively higher average prices and maxes through 2050.
A major floor 16.0% below — a decisive break under it would weaken the trend.
The nearest floor, 6.7% below — buyers have tended to step in here.
The nearest ceiling, 4.4% above — a clean break opens room to run.
A major ceiling 39.1% above — clearing it would confirm fresh momentum.
Key HIND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HIND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.21 | Buy | $2.22 | Buy |
| MA 10 | $2.20 | Buy | $2.21 | Buy |
| MA 20 | $2.19 | Buy | $2.20 | Buy |
| MA 50 | $2.15 | Buy | $2.22 | Buy |
| MA 100 | $2.31 | Sell | $3.13 | Sell |
| MA 200 | $3.34 | Sell | $63.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.35 | Neutral |
| Stoch RSI (14) | 68.62 | Neutral |
| CCI (20) | 75.51 | Neutral |
| Williams %R (14) | -25.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 6.13 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 75.00 | Neutral |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 57.87 | Neutral |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 2.20 | Buy |
| ADX (14) | 8.85 | Neutral |
| ATR (14) | 0.05 | Info |
Near term, the sentiment is NEUTRAL with RSI14 at 50. The price action sits around the SMA50, which is $2.17, while the SMA200 sits higher at $3.66. Support is at $1.89 and resistance at $2.35, suggesting a shallow test of the base with potential for a move toward the resistance level.
The 30-day range is $1.72 to $2.74, indicating a relatively tight, yet range-bound movement in the near term. Annualized volatility is high at 70%, underscoring elevated swings within the broader price band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.89 | $2.25 | $3.28 | 0% | Neutral | |
| $2.12 | $2.74 | $3.78 | +22% | Bullish | |
| $2.30 | $3.09 | $4.45 | +37% | Bullish | |
| $2.11 | $2.92 | $4.37 | +30% | Bullish | |
| $1.76 | $2.51 | $3.87 | +11% | Neutral | |
| $1.89 | $2.76 | $4.36 | +23% | Bullish | |
| $1.91 | $2.85 | $4.62 | +27% | Bullish | |
| $2.12 | $3.24 | $5.35 | +44% | Bullish | |
| $2.39 | $3.72 | $6.27 | +66% | Bullish | |
| $2.26 | $3.60 | $6.18 | +60% | Bullish | |
| $2.79 | $4.89 | $9.03 | +117% | Bullish | |
| $3.28 | $6.83 | $14.00 | +203% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.89 | $2.25 | $2.82 | +0.00% |
| August 2026 | $2.07 | $2.46 | $3.02 | +9.25% |
| September 2026 | $2.01 | $2.41 | $3.00 | -2.04% |
| October 2026 | $1.97 | $2.38 | $3.01 | -0.96% |
| November 2026 | $2.06 | $2.50 | $3.19 | +5.00% |
| December 2026 | $2.09 | $2.56 | $3.28 | +2.10% |
Click any year to see its month-by-month HIND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect HIND to range from $1.89 to $3.28 through 2026. The $2.25 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The HIND price prediction for 2027 points to an average of $2.74 (low $2.12, high $3.78) — a potential gain of +22% on today's $2.25. Buyers look set to stay in control over this stretch.
In 2028, HIND is projected to trade between $2.30 and $4.45, averaging $3.09 — a potential gain of +37% from today's $2.25. That is up +13% on the projected 2027 average. Momentum favours further upside here.
Vyome Holdings, Inc.'s 2029 outlook centres on $2.92, within a $2.11 to $4.37 range. That is -5% versus the projected 2028 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, HIND could reach as high as $3.87, with a base case around $2.51 and support toward $1.76 — roughly +11% from $2.25. Price action looks broadly range-bound.
Expect HIND to range from $1.89 to $4.36 through 2031. The $2.76 average target implies a +23% move from current prices. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The HIND price prediction for 2032 points to an average of $2.85 (low $1.91, high $4.62) — a potential gain of +27% on today's $2.25. Momentum favours further upside here.
In 2033, HIND is projected to trade between $2.12 and $5.35, averaging $3.24 — a potential gain of +44% from today's $2.25. That is up +14% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Vyome Holdings, Inc.'s 2034 outlook centres on $3.72, within a $2.39 to $6.27 range. That is up +15% on the projected 2033 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2035, HIND could reach as high as $6.18, with a base case around $3.60 and support toward $2.26 — roughly +60% from $2.25. Buyers look set to stay in control over this stretch.
Expect HIND to range from $2.79 to $9.03 through 2040. The $4.89 average target implies a +117% move from current prices. That is up +36% on the projected 2035 average. Momentum favours further upside here.
The HIND price prediction for 2050 points to an average of $6.83 (low $3.28, high $14.00) — a potential gain of +203% on today's $2.25. Buyers look set to stay in control over this stretch.
Investing $1,000 in HIND today (≈ 444.444444 HIND) could be worth
$3,033.62
+$2,033.62 (+203%) by 2050 · US Dollar
Based on the average projected HIND price of $6.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HINDwould be worth at today's price.
$1,000 invested in HIND on Jul 10, 2025 (≈ 102.459014 HIND) would be worth
$230.53
-$769.47 (-76.9%) today · 0.23× · US Dollar
Based on a HIND entry price of $9.76 vs. today's $2.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.3 | $978.26 | -2.2% |
| 1 month ago | $2.17 | $1,034.48 | +3.4% |
| 3 months ago | $2.19 | $1,027.4 | +2.7% |
| 6 months ago | $3.23 | $696.59 | -30.3% |
| 1 year ago | $9.76 | $230.53 | -76.9% |
| All time (5.0y) ago | $1,331,100 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HIND forecast.
Our base-case forecast reaches $4.50 around 2040.
Implied market cap at $4.50: $31.58M
Looking further out, the multi-year forecast shows a path of rising averages and growing upside. In 2027 the average is $2.70 with a 24.4% ROI and bullish sentiment, followed by 2028 at $3.00 (38.4% ROI) and 2029 at $2.75 (26.6% ROI).
By 2030 the average is $2.43 with a 12.1% ROI, and 2031–2032 remain bullish with 2031 at $2.73 (25.7% ROI) and 2032 at $2.72 (25.2% ROI). In 2033 the average climbs to $3.14 (44.7% ROI) and 2034 to $3.67 (69.2% ROI), with 2035 at $3.43 (58.2% ROI).
The forecast accelerates into the 2040s, with 2040 at $4.82 (122.2% ROI) and 2050 at $6.46 (197.6% ROI). The sentiment through these years is bullish, reflecting a sustained upward trajectory in the modeled path, though 2026 and 2030 carry neutral signals. These figures are estimates and not guarantees, reflecting modeled projections across the horizon.
Tap a question to reveal the answer.
In 2030, the average forecast is $2.43 with a min of $1.71 and a max of $3.76; ROI 12.1%; sentiment NEUTRAL.
The near term is neutral (2026) with bullish momentum developing in 2027 and continuing through 2050, showing an average price path up to $6.46 by 2050 and a max of $13.28, with ROI reaching 197.6%. These are estimates, not guarantees.
Yes. The forecast shows max prices of $5.20 in 2033, $6.20 in 2034, $8.92 in 2040, and $13.28 in 2050, indicating potential to exceed $5 over the horizon.
The 30-day range is $1.72 to $2.74.
Current price is $2.17; market cap is $15.23M; rank 4688; sector Healthcare.
Vyome Holdings, Inc. Community Discussion
0Share your Vyome Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.